Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Pasquale, Giovanni ^a   Dicembrini, Ilaria ^b   Raimondi, Laura ^b   Pagano, Claudio ^c   Egan, Josephine M ^d   Cozzi, Andrea ^b   Cinci, Lorenzo ^b   Loreto, Andrea ^b   Manni, Maria E ^b   Berretti, Silvia ^b   Morelli, Annamaria ^b   Zheng, Changyu ^a   Michael, Drew G ^a   Maggi, Mario ^b   Vettor, Roberto ^c   Chiorini, John A ^a   Mannucci, Edoardo ^e   Rotella, Carlo M ^b  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e Careggi Teaching Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; EXENDIN 4; LEPTIN; PARVOVIRUS 5 VECTOR; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEASIBILITY STUDY; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SALIVARY GLAND; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DEPENDOVIRUS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MICE; OBESITY; PEPTIDES; RATS; RATS, ZUCKER; RECEPTORS, GLUCAGON; SALIVARY GLANDS; VENOMS; WEIGHT GAIN;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 84863760366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040074     Document Type: Article

References (44)

1. Parker HE, Reimann F, Gribble FM, (2010) Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 12: e1.
2. Gribble FM, RD Lawrence Lecture, (2008) Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. Diabet Med 25(8): 889-94.
3. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, et al. (2000) Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med 17(10): 713-9.
4. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ, (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50(3): 609-13.
5. Zander M, Madsbad S, Madsen JL, Holst JJ, (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359(9309): 824-30.
6. Neumiller JJ, (2009) Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 49: S16-S29.
7. Madsbad S, (2009) Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23(4): 463-77.
8. Dicembrini I, Pala L, Rotella CM, (2011) From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Exp Diabetes Res 2011: 898913.
9. Srivastava A, (2008) Adeno-associated virus-mediated gene transfer. J Cell Biochem 105(1): 17-24.
10. Voutetakis A, Cotrim AP, Rowzee A, Zheng C, Rathod T, et al. (2010) Systemic delivery of bioactive glucagon-like peptide 1 after adenoviral-mediated gene transfer in the murine salivary gland. Endocrinology 151(9): 4566-72.
11. Kumar M, Hunag Y, Glinka Y, Prud'homme GJ, Wang Q, (2007) Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther 14(2): 162-72.
12. Liu R, Li Y, Hu R, Jin T, Deng S, et al. (2010) A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis. Biochem Biophys Res Commun 403(2): 172-7.
13. Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, et al. (2008) Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 16(11): 1805-12.
14. Lee Y, Kwon MK, Kang ES, Park YM, Choi SH, et al. (2008) Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. J Gene Med 10(3): 260-8.
15. Choi S, Oh S, Lee M, Kim SW, (2005) Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes. Mol Ther 12(5): 885-91.
16. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, et al. (2007) Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56(6): 1671-9.
17. Rowzee AM, Cawley NX, Chiorini JA, Di Pasquale G, (2011) Glucagon-like peptide-1 gene therapy. Exp Diabetes Res 2011: 601047.
18. Sumner-Jones SG, Davies LA, Varathalingam A, Gill DR, Hyde SC, (2006) Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways. Gene Ther 13(24): 1703-13.
19. Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, et al. (2006) Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 13(5): 967-75.
20. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, et al. (2009) Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113(4): 797-806.
21. Daya S, Berns KI, (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (214): 583-93.
22. Mandel RJ, (2010) CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 12(2): 240-7.
23. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358(21): 2231-9.
24. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, et al. (2004) Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125(2): 509-21.
25. Diaz-Nido J, (2010) NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs 11(7): 813-22.
26. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, et al. (2010) Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18(3): 643-50.
27. Kwon I, Schaffer DV, (2008) Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 25(3): 489-99.
28. Katano H, Kok MR, Cotrim AP, Yamano P, Schmidt M, et al. (2006) Enhanced transduction of mouse salivary glands with AAV5-based vectors. Gene Ther 13(7): 594-601.
29. Voutetakis A, Bossis I, Kok MR, Zhang W, Wang J, et al. (2005) Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J Endocrinol 185(3): 363-72.
30. He X, Goldsmith CM, Marmary Y, Wellner RB, Parlow AF, et al. (1998) Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. Gene Ther 5(4): 537-41.
31. Adriaansen J, Perez P, Zheng C, Collins MT, Baum BJ, (2011) Human parathyroid hormone is secreted primarily into the bloodstream after rat parotid gland gene transfer. Hum Gene Ther 22(1): 84-92.
32. Samani Y, Baum BJ, (2011) Gene delivery in salivary glands: From the bench to the clinic. Biochimica et Biophysica Acta. In press.
33. Di Pasquale G, Rzadzinska A, Schneider ME, Bossis I, Chiorini JA, et al. (2005) A novel bovine virus efficiently transduces inner ear neuroepithelial cells. Mol Ther 11(6): 849-55.
34. Beutler AS, Banck MS, Bach FW, Gage FH, Porreca F, et al. (1995) Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts. J Neurochem. 64(2): 475-81.
35. Doyle ME, Greig NH, Holloway HW, Betkey JA, Bernier M, et al. (2001) Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. Endocrinology 142(10): 4462-8.
36. Breslin WL, Strohacker K, Carpenter KC, Esposito L, McFarlin BK, (2010) Weight gain in response to high-fat feeding in CD-1 male mice. Lab Anim 44(3): 231-7.
37. Oana F, Takeda H, Hayakawa K, Matsuzawa A, Akahane S, et al. (2005) Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin. Metabolism 54(8): 995-1001.
38. Zhao J, Gillam ME, Taylor C, Weiler HA, (2011) Deposition of docohexaenoic acid (DHA) i limited in forebrain of young obese fa/fa Zucker rats fed a dier high in α-linoleic acid but devoid of DHA. Journal of Nutritional Chemistry 22: 835-42.
39. Rotella CM, Pala L, Mannucci E, (2005) Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 28(8): 746-58.
40. Monami M, Marchionni M, Mannucci E, (2009) Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 160(6): 909-17.
41. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, et al. (2009) NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701): 1606-16.
42. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ, (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43(4): 535-9.
43. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatideon glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30(6): 1487-93.
44. Knudsen LB, Madsen LW, Andersen S, Almholt K, de Boer AS, et al. (2010) Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 151(4): 1473-86.